MCID: HPT019
MIFTS: 60

Hepatic Encephalopathy

Categories: Liver diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Hepatic Encephalopathy

MalaCards integrated aliases for Hepatic Encephalopathy:

Name: Hepatic Encephalopathy 12 76 53 37 55 15 73
Portal-Systemic Encephalopathy 12
Encephalopathy, Hepatic 53
Hepatoencephalopathy 53

Classifications:



External Ids:

Disease Ontology 12 DOID:13413
ICD10 33 K72
ICD9CM 35 572.2
MeSH 44 D006501
NCIt 50 C79596
SNOMED-CT 68 13920009
KEGG 37 H01506
UMLS 73 C0019151

Summaries for Hepatic Encephalopathy

NIH Rare Diseases : 53 Hepatic encephalopathy is a syndrome observed in some patients with cirrhosis. It is defined as a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction, when other known brain disease has been excluded. Signs and symptoms may be debilitating, and they can begin mildly and gradually, or occur suddenly and severely. They may include personality or mood changes, intellectual impairment, abnormal movements, a depressed level of consciousness, and other symptoms. There are several theories regarding the exact cause, but development of the condition is probably at least partially due to the effect of substances that are toxic to nerve tissue (neurotoxic), which are typically present with liver damage and/or liver disease. Treatment depends upon the severity of mental status changes and upon the certainty of the diagnosis.

MalaCards based summary : Hepatic Encephalopathy, also known as portal-systemic encephalopathy, is related to hepatic coma and alcoholic liver cirrhosis. An important gene associated with Hepatic Encephalopathy is TSPO (Translocator Protein), and among its related pathways/superpathways are Circadian entrainment and Immune response IL-23 signaling pathway. The drugs Metformin and Lactulose have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A brain disease that is characterized by loss of brain function, the occurrence of confusion, altered level of consciousness, and coma that results when the liver is unable to remove toxins from the blood.

Wikipedia : 76 Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Onset may... more...

Related Diseases for Hepatic Encephalopathy

Diseases related to Hepatic Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 225)
# Related Disease Score Top Affiliating Genes
1 hepatic coma 32.5 ALB F2 GPT TSPO
2 alcoholic liver cirrhosis 32.4 ALB F2 SLC17A5
3 liver cirrhosis 32.1 ALB F2 GPT SLC17A5
4 alcoholic hepatitis 31.5 ALB F2 GPT IL6 SLC17A5 TNF
5 acute liver failure 31.4 ALB F2 GC GPT SLC17A5 TSPO
6 schistosomiasis 30.4 ALB F2 TNF
7 infantile liver failure syndrome 1 30.3 ALB F2 GPT SLC17A5
8 hepatitis 30.1 F2 GPT SLC17A5 TNF
9 portal hypertension 30.1 ALB F2 GPT TNF
10 brain edema 30.1 ALB GLUL IL6 SLC1A2 SLC25A13
11 peritonitis 30.1 ALB F2 IL6 TNF
12 wilson disease 29.9 ALB F2 GPT
13 meningitis 29.8 ALB IL6 TNF
14 liver disease 29.7 ALB F2 GPT IL6 SLC17A5 SLC25A13
15 hepatitis b 29.6 ALB F2 GPT SLC17A5 TNF
16 viral infectious disease 29.4 GPT IL6 TNF
17 viral hepatitis 29.1 ALB F2 GPT SLC17A5 TNF
18 schizophrenia 29.0 MAOA MAOB NOS1 SLC1A2 TSPO
19 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 12.5
20 combined oxidative phosphorylation deficiency 1 11.9
21 congenital extrahepatic portosystemic shunt 11.3
22 encephalopathy 11.2
23 3-hydroxyacyl-coa dehydrogenase deficiency 11.1
24 hepatic veno-occlusive disease 11.0
25 hepatorenal syndrome 11.0
26 carnitine palmitoyltransferase i deficiency , muscle 11.0
27 antipyrine metabolism 10.3 ALB F2
28 non-a-e hepatitis 10.3 ALB F2
29 leukomalacia 10.3 IL6 TNF
30 epstein-barr virus hepatitis 10.3 ALB F2
31 scorpion envenomation 10.3 IL6 TNF
32 fournier gangrene 10.2 ALB F2
33 angioimmunoblastic lymphadenopathy with dysproteinemia 10.2 IL6 TNF
34 critical limb ischemia 10.2 IL6 TNF
35 abdominal tuberculosis 10.2 ALB F2
36 streptococcal toxic-shock syndrome 10.2 IL6 TNF
37 sudden sensorineural hearing loss 10.2 F2 IL6
38 juvenile ankylosing spondylitis 10.2 IL6 TNF
39 cardiogenic shock 10.2 IL6 TNF
40 marburg hemorrhagic fever 10.2 F2 TNF
41 null-cell leukemia 10.2 IL6 TNF
42 retinitis pigmentosa 55 10.2 IL6 TNF
43 anca-associated vasculitis 10.2 IL6 TNF
44 atypical depressive disorder 10.2 MAOA MAOB
45 glossitis 10.2 IL6 TNF
46 chronic graft versus host disease 10.2 ALB TNF
47 laryngitis 10.2 IL6 TNF
48 hypersensitivity reaction type iii disease 10.2 ALB IL6 TNF
49 keratoconjunctivitis sicca 10.2 ALB IL6 TNF
50 hemorrhagic fever with renal syndrome 10.2 ALB IL6 TNF

Comorbidity relations with Hepatic Encephalopathy via Phenotypic Disease Network (PDN): (show all 26)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alcohol Abuse Alcoholic Hepatitis
Alcoholic Liver Cirrhosis Chronic Kidney Failure
Decubitus Ulcer Deficiency Anemia
Encephalopathy Esophageal Varix
Heart Disease Hepatitis
Hepatocellular Carcinoma Hepatorenal Syndrome
Hypersplenism Liver Disease
Neutropenia Portal Hypertension
Portal Vein Thrombosis Primary Biliary Cirrhosis
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Urea Cycle Disorder

Graphical network of the top 20 diseases related to Hepatic Encephalopathy:



Diseases related to Hepatic Encephalopathy

Symptoms & Phenotypes for Hepatic Encephalopathy

MGI Mouse Phenotypes related to Hepatic Encephalopathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 F2 GLS GLUL IL6 MAOA MAOB
2 homeostasis/metabolism MP:0005376 10.13 ALB F2 GC GLUL IL6 MAOA
3 cellular MP:0005384 10.02 ALB GLUL IL6 MAOB NOS1 SLC17A5
4 mortality/aging MP:0010768 9.9 ALB F2 GLS GLUL IL6 NOS1
5 liver/biliary system MP:0005370 9.8 ALB GLUL IL6 NOS1 SLC25A13 TNF
6 nervous system MP:0003631 9.65 F2 GLUL IL6 MAOA MAOB NOS1
7 normal MP:0002873 9.17 ALB F2 GLS GLUL NOS1 SLC1A2

Drugs & Therapeutics for Hepatic Encephalopathy

Drugs for Hepatic Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 282)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 14219 4091
2
Lactulose Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4618-18-2 11333
3
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
4
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
5
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80621-81-4 6436173
6
Magnesium oxide Approved Phase 4 1309-48-4 14792
7
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
8
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
9
Carvedilol Approved, Investigational Phase 4,Not Applicable 72956-09-3 2585
10
Propranolol Approved, Investigational Phase 4,Phase 3,Not Applicable 525-66-6 4946
11
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2 142217-69-4 153941
12
Norfloxacin Approved Phase 4,Phase 3 70458-96-7 4539
13
Insulin Aspart Approved Phase 4 116094-23-6 16132418
14
Midodrine Approved Phase 4,Phase 2,Phase 3,Not Applicable 133163-28-7, 42794-76-3 4195
15
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
16
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
17
Promethazine Approved, Investigational Phase 4 60-87-7 4927
18
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
19
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
20
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
21
Mannitol Approved, Investigational Phase 4,Not Applicable 69-65-8 453 6251
22
Terlipressin Approved, Investigational Phase 4,Not Applicable 14636-12-5 72081
23
Lypressin Approved Phase 4,Not Applicable 50-57-7
24
Tolvaptan Approved Phase 4,Phase 3 150683-30-0 216237
25
Tranexamic Acid Approved Phase 4 1197-18-8 5526
26
chenodeoxycholic acid Approved Phase 4,Phase 3 474-25-9 10133
27
Ornithine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 3184-13-2, 70-26-8 6262
28
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
29
Tenofovir Experimental, Investigational Phase 4,Not Applicable 147127-20-6 464205
30 Hypoglycemic Agents Phase 4
31 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Aspartic Acid Phase 4,Phase 3,Phase 2,Not Applicable
34 Excitatory Amino Acid Agonists Phase 4,Phase 3,Phase 2,Not Applicable
35 N-Methylaspartate Phase 4,Phase 3,Phase 2,Not Applicable
36 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Not Applicable
38 GABA Agents Phase 4,Phase 1,Phase 2,Not Applicable
39 Adjuvants, Anesthesia Phase 4,Not Applicable
40 Psychotropic Drugs Phase 4,Not Applicable
41 Anti-Anxiety Agents Phase 4,Not Applicable
42 Hypnotics and Sedatives Phase 4,Phase 2,Not Applicable
43 Anesthetics, Intravenous Phase 4,Not Applicable
44 Central Nervous System Depressants Phase 4,Phase 2,Not Applicable
45 Anesthetics Phase 4,Phase 2,Not Applicable
46 Anesthetics, General Phase 4,Not Applicable
47 GABA Modulators Phase 4,Phase 1,Phase 2,Not Applicable
48 Tranquilizing Agents Phase 4,Not Applicable
49 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 rifamycin SV Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 305)
# Name Status NCT ID Phase Drugs
1 Metformin Experience on Minimal Hepatic Encephalopathy Unknown status NCT02470546 Phase 4 Metformin;Placebo
2 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
3 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
4 Efficacy of Combined Oral L-Ornithine-L-Aspartate and Lactulose in Patients With Hepatic Encephalopathy Unknown status NCT00740142 Phase 4 L-ornithine-L-aspartate and lactulose;placebo and lactulose
5 Trial Comparing Sedation for Endoscopy With Propofol Versus Midazolam in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
6 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
7 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
8 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
9 Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis Unknown status NCT01282398 Phase 4 Simvastatin;placebo
10 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
11 Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
12 The Effect of Carvedilol VS Endoscopic Therapy in Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding Unknown status NCT02695732 Phase 4 Carvedilol
13 The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding Unknown status NCT02385422 Phase 4 Carvedilol;Propranolol
14 The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites Unknown status NCT02755701 Phase 4 Branched-chain Amino Acid;Placebo
15 Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding Completed NCT02158182 Phase 4 Lactulose;L-ornithine L-aspartate;Rifaximin;Placebo
16 Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy Completed NCT01559519 Phase 4 Albumin
17 Effects of Proteins in Patients With Cirrhosis and Prior Hepatic Encephalopathy Completed NCT00955500 Phase 4
18 Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate Completed NCT01847651 Phase 4 LOLA or placebo
19 Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy. Completed NCT01041755 Phase 4 L-ornithine-L-aspartate;Lactose
20 Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life Completed NCT00375375 Phase 4 Lactulose
21 L-ornithine L-aspartate in Overt Hepatic Encephalopathy Completed NCT01722578 Phase 4 L-ornithine L-aspartate;Placebo
22 Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy Completed NCT02019784 Phase 4 Rifaximin-α;Placebo Oral Tablet
23 Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis Completed NCT00886925 Phase 4 Albumin;Sodium chloride 0.9%
24 The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy Completed NCT01842581 Phase 4 Rifaximin;Rifaximin and Lactulose
25 Branched Chain Aminoacid Supplementation in Patients With Liver Cirrhosis Completed NCT02023229 Phase 4
26 Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation Completed NCT00839358 Phase 4 albumin;Midodrine;Placebo
27 Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
28 Ramelteon for Treatment of Insomnia in Cirrhosis Completed NCT03091738 Phase 4 Ramelteon Pill
29 Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis Completed NCT01943617 Phase 4 Entecavir;Thymosin-α
30 Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention Completed NCT01542801 Phase 4 Norfloxacin;ciprofloxacin
31 Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure" Completed NCT01201720 Phase 4
32 Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects Completed NCT01846455 Phase 4 2.0mg Buprenorphine/0.5mg Naloxone;Promethazine
33 Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy Recruiting NCT01846663 Phase 4 Placebo;Rifaximin
34 PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy Recruiting NCT03100513 Phase 4 Lactulose;Polyethylene Glycol
35 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Recruiting NCT02401490 Phase 4 Human albumin;Placebo
36 Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding Recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
37 Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Recruiting NCT02308111 Phase 4 Obeticholic Acid (OCA);Placebo
38 Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis Patients Recruiting NCT02849132 Phase 4 Entecavir
39 Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial Recruiting NCT02190357 Phase 4 Rifaximin
40 Study of OCA Evaluating Pharmacokinetics and Safety in Patients With PBC and Hepatic Impairment Recruiting NCT03633227 Phase 4 Obeticholic Acid (OCA);Placebo
41 Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C Recruiting NCT03633279 Phase 4 Branched chain amino acid;Placebo
42 Efficacy of Terlipressin Therapy in Acute Variceal Haemorrhage After EVL Recruiting NCT03584087 Phase 4 Normal Saline;Terlipressin
43 Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy Not yet recruiting NCT03077217 Phase 4 Rifaximin
44 Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load Not yet recruiting NCT02308319 Phase 4 Tenofovir disoproxil fumarate
45 Beta-blockers for Oesophageal Varices Not yet recruiting NCT03776955 Phase 4 Carvedilol
46 Quality of Life and Nutritional Improvements in Cirrhotic Patients Terminated NCT01842113 Phase 4 Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo
47 Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia Terminated NCT01890694 Phase 4 Tolvaptan;Placebo
48 Effect of Intrathoracic Pressure Regulation on Traumatic Brain Injury Terminated NCT01824589 Phase 4
49 Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease Withdrawn NCT01654939 Phase 4 Rifaximin
50 ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study Unknown status NCT01798329 Phase 3

Search NIH Clinical Center for Hepatic Encephalopathy

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Hepatic Encephalopathy

Anatomical Context for Hepatic Encephalopathy

MalaCards organs/tissues related to Hepatic Encephalopathy:

41
Liver, Brain, Testes, Cortex, Eye, Kidney, Small Intestine

Publications for Hepatic Encephalopathy

Articles related to Hepatic Encephalopathy:

(show top 50) (show all 1539)
# Title Authors Year
1
Disrupted Brain Intrinsic Networks and Executive Dysfunction in Cirrhotic Patients without Overt Hepatic Encephalopathy. ( 29422882 )
2018
2
Comparison of prognostic systems in cirrhotic patients with hepatic encephalopathy ( 29914250 )
2018
3
Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis. ( 29428113 )
2018
4
Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy? ( 29394969 )
2018
5
Covert hepatic encephalopathy leads to distinct alterations in the emotional state, independently of MELD-Score. ( 29341039 )
2018
6
Patient Acceptance of Lactulose Varies Between Indian and American Cohorts: Implications for Comparing and Designing Global Hepatic Encephalopathy Trials. ( 29892171 )
2018
7
Baicalin reverses the impairment of synaptogenesis induced by dopamine burden via the stimulation of GABA<sub>A</sub>R-TrkB interaction in minimal hepatic encephalopathy. ( 29404643 )
2018
8
Effect of sirolimus on liver cirrhosis and hepatic encephalopathy of common bile duct-ligated rats. ( 29444470 )
2018
9
Refractory Hepatic Encephalopathy After Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors and Outcomes with Revision. ( 29872892 )
2018
10
Aberrant Brain Bile Acid Signaling and Cholesterol Accumulation: A New Look at Mechanisms in Hepatic Encephalopathy. ( 29928680 )
2018
11
Identification of modules of hepatic encephalopathy based on protein-protein network and gene expression data. ( 29849776 )
2018
12
CT Scan Is Still a Valuable Tool to Assess Hepatic Encephalopathy Pathophysiology in Both Acute and Chronic Liver Diseases. ( 29912129 )
2018
13
Hepatic encephalopathy: causes and health-related burden. ( 29411993 )
2018
14
Neuroinflammation in acute hepatic encephalopathy rats: imaging and therapeutic effectiveness evaluation using <sup>11</sup>C-PK11195 and <sup>18</sup>F-DPA-714 micro-positron emission tomography. ( 29968208 )
2018
15
Prevalence of and Factors Associated With Minimal Hepatic Encephalopathy in Patients With Cirrhosis of Liver. ( 29892178 )
2018
16
Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin. ( 29856063 )
2018
17
Multimodal MR imaging in hepatic encephalopathy: state of the art. ( 29374342 )
2018
18
Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis. ( 29881992 )
2018
19
Prediction of Hepatic Encephalopathy: Why disregard well known risk factors? ( 29377250 )
2018
20
Stroop Test Validation to Screen for Minimal Hepatic Encephalopathy in Pediatric Extrahepatic Portal Venous Obstruction. ( 29373442 )
2018
21
Impact of intestinal mannitol on hyperammonemia, oxidative stress and severity of hepatic encephalopathy in the ED. ( 29352675 )
2018
22
Hepatic encephalopathy and cirrhotic cardiomyopathy in intensive care unit. ( 29624025 )
2018
23
Improving Quality of Care for People with Hepatic Encephalopathy. ( 29411992 )
2018
24
Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. ( 29383024 )
2018
25
Re: Prediction of Hepatic Encephalopathy: why disregard well known risk factors? ( 29365345 )
2018
26
Conservative management of severe serotonin syndrome with coma, myoclonus, and crossed-extensor reflex complicated by hepatic encephalopathy. ( 29686575 )
2018
27
FXR-Mediated Cortical Cholesterol Accumulation Contributes to the Pathogenesis of Type A Hepatic Encephalopathy. ( 29928671 )
2018
28
Aberrant topological organization of the functional brain network associated with prior overt hepatic encephalopathy in cirrhotic patients. ( 29846883 )
2018
29
Direct comparison of the thioacetamide and azoxymethane models of Type A hepatic encephalopathy in mice. ( 29895352 )
2018
30
Efficacy of different drugs in the treatment of minimal hepatic encephalopathy: A network meta-analysis involving 826 patients based on 10 randomized controlled trials. ( 29932239 )
2018
31
Effect of Post-Traumatic Stress Disorder on Cognitive Function and Covert Hepatic Encephalopathy Diagnosis in Cirrhotic Veterans. ( 29313245 )
2018
32
EDITORIAL that refers to article 'Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study'. ( 29430750 )
2018
33
Diagnosis and management of hepatic encephalopathy. ( 29411990 )
2018
34
Rifaximin versus metronidazole in management of acute episode of hepatic encephalopathy: An open labeled randomized clinical trial. ( 29935863 )
2018
35
Coil-Assisted Retrograde Transvenous Obliteration (CARTO): An Alternative Treatment Option for Refractory Hepatic Encephalopathy. ( 29899437 )
2018
36
Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients. ( 29863286 )
2018
37
Effects of Alcohol on the Brain in Cirrhosis: Beyond Hepatic Encephalopathy. ( 29417604 )
2018
38
Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy. ( 29844325 )
2018
39
Osmotic Shifts, Cerebral Edema, and Neurologic Deterioration in Severe Hepatic Encephalopathy. ( 29341965 )
2018
40
Acute liver failure and hepatic encephalopathy in exertional heat stroke. ( 30061127 )
2018
41
Hepatic encephalopathy: Another brick in the wall. ( 30414737 )
2018
42
Impaired Tactile Temporal Discrimination in Patients With Hepatic Encephalopathy. ( 30425672 )
2018
43
Hepatic Encephalopathy in Patients in Lviv (Ukraine). ( 30425951 )
2018
44
Neuroprotective Effect of Nortriptyline in Overt Hepatic Encephalopathy Through Attenuation of Mitochondrial Dysfunction. ( 30428281 )
2018
45
Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy. ( 30428474 )
2018
46
Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic Encephalopathy. ( 30439761 )
2018
47
A Mean Field Model of Acute Hepatic Encephalopathy. ( 30440882 )
2018
48
Establishment and evaluation of a model for predicting 3-month mortality in Chinese patients with hepatic encephalopathy. ( 30443767 )
2018
49
Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. ( 30444745 )
2018
50
Preliminary experience with single fecal microbiota transplant for treatment of recurrent overt hepatic encephalopathy-A case series. ( 30474827 )
2018

Variations for Hepatic Encephalopathy

Expression for Hepatic Encephalopathy

LifeMap Discovery
Genes differentially expressed in tissues of Hepatic Encephalopathy patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 PSPH phosphoserine phosphatase Brain - 4.35 0.000
Search GEO for disease gene expression data for Hepatic Encephalopathy.

Pathways for Hepatic Encephalopathy

Pathways related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.67 GLS GLUL MAOA MAOB NOS1 SLC1A2
2
Show member pathways
12.36 F2 IL6 NOS1 TNF
3
Show member pathways
12.04 ALB F2 IL6 TNF
4
Show member pathways
11.84 F2 IL6 TNF
5 11.81 IL6 NOS1 TNF
6
Show member pathways
11.78 NOS1 SLC1A2 TNF
7 11.77 IL6 MAOA TNF
8 11.59 GLS GLUL MAOA
9
Show member pathways
11.3 MAOA MAOB NOS1
10
Show member pathways
11.07 MAOA NOS1 TNF
11
Show member pathways
10.94 GLS GLUL GPT
12 10.93 IL6 TNF
13 10.85 IL6 TNF
14
Show member pathways
10.69 MAOA MAOB
15 10.68 GLS GLUL GPT
16 10.64 MAOA MAOB
17
Show member pathways
10.59 MAOA MAOB
18
Show member pathways
10.34 GLUL SLC1A2
19
Show member pathways
10.34 GLS GLUL GPT NOS1

GO Terms for Hepatic Encephalopathy

Cellular components related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.17 GLS GLUL MAOA MAOB NOS1 SLC25A13
2 blood microparticle GO:0072562 9.13 ALB F2 GC

Biological processes related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 anion transport GO:0006820 9.48 SLC17A5 TSPO
2 positive regulation of chemokine production GO:0032722 9.46 IL6 TNF
3 glutamate secretion GO:0014047 9.43 GLS SLC1A2
4 L-glutamate transmembrane transport GO:0015813 9.4 SLC1A2 SLC25A13
5 neurotransmitter catabolic process GO:0042135 9.37 MAOA MAOB
6 negative regulation of lipid storage GO:0010888 9.32 IL6 TNF
7 dopamine catabolic process GO:0042420 9.26 MAOA MAOB
8 positive regulation of neuroinflammatory response GO:0150078 9.16 IL6 TNF
9 cellular amino acid biosynthetic process GO:0008652 9.13 GLS GLUL GPT
10 positive regulation of glial cell proliferation GO:0060252 8.8 IL6 TNF TSPO

Molecular functions related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 L-glutamate transmembrane transporter activity GO:0005313 8.96 SLC1A2 SLC25A13
2 primary amine oxidase activity GO:0008131 8.62 MAOA MAOB

Sources for Hepatic Encephalopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....